All News

As treatment delays become more common – especially with the COVID-19 pandemic – delays as much as four weeks can impact the risk for mortality in seven different types of cancer.

As the treatment landscape for multiple myeloma continues to evolve, it is key for patients to find a specialist in the field, ask questions and learn more about their options.

Data from the trial that led to the Food and Drug Administration approval demonstrated that Margenza plus chemotherapy reduced the risk of disease progression or death in patients with metastatic HER2-positive breast cancer by 24%, compared with Herceptin plus chemotherapy.

Advancements in the diagnosis and staging of multiple myeloma continue to shape treatment decisions and improve outcomes.

A cancer survivor writes about the indirect consequences of COVID-19 on her and others.

In an interview with CURE®, Dr. Giada Bianchi provides patients an overview of myeloma, including symptoms and risk factors of the disease people should look out for.

After a median follow-up of 9.9 months, 38% of the trial participants experienced some degree of tumor shrinkage after receiving Opdivo in combination with Yervoy.

The complexity of multiple myeloma can make it difficult to treat, but with complexity comes more avenues for researchers to explore what treatments work best. Recently, CURE® spoke with an expert from Dana-Farber Cancer Institute on what patients can expect to see from the clinical setting.

If a patient with cancer is no longer receiving active treatment and there are no signs of active disease, an expert from The University of Texas MD Anderson Cancer Center suggests they should have a good response to the COVID-19 vaccine, but direct data on this are not yet available.

A cancer survivor debates getting the vaccine and seeks more information about its side effects.

This study also found that women with higher waist circumferences had a higher risk for cancer-related and all-cause death compared with those with lower waist circumferences.

In this most stressful of seasons, these seven specific steps can bring the joy back to the Holidays for those patients going through cancer treatment this time of year.

Results from this blood test may help develop informed treatment plans for pancreatic cancer and potentially help patients avoid unnecessary treatment.

On social media, in honor of the holiday season, CURE® recently asked its readers to share some of the best gifts they either given or received during their cancer treatment.

This holiday I have unfortunate news that may turn out to be nothing, but sometimes it's better to keep our loved ones in the dark till we know more.

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.

A caregiver uses poetry to work through their husband's cancer journey.

A new grant program offers financial assistance for patients with mesothelioma who must travel for cancer care.

Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.

Don't just get the cancer caregiver in your life a gift that will only last a month, get them something that lasts year-round with these three ways you can help as they help you on the cancer journey.

Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

The Food and Drug Administration has issued the first emergency use authorization for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 in people 16 years old and older.

An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

A recent visit to the doctor helped to put into perspective the concerns I have for the new year and COVID-19, especially for those struggling with breast cancer and its ramifications.

From actor Jason Momoa gifting a trident to a young fan of the superhero movie “Aquaman” who is receiving treatment for an aggressive form of brain cancer, to data demonstrating the regular consumption of chili peppers is associated with lower cancer mortality rates, here’s everything happening in the cancer landscape this week.

While breast cancer survivors had a 45% higher risk of going into preterm labor, there were no significant increased risks of congenital defects or other pregnancy or delivery complications.

The FDA’s Vaccines and Related Biological Products Advisory Committee voted in favor of granting BNT162b2, the COVID-19 vaccine developed by Pfizer and BioNTech, emergency use authorization.